The cash flow of REGAL REXNORD CORP over the past 10 years
Chart REGAL REXNORD CORP: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, REGAL REXNORD CORP's operating cash flow was $990.8M and its capital expenditures $97.7M, leaving free cash flow of $893.1M. Free cash flow was above zero in all 10 years shown. It ranged from $226.7M in fiscal 2017 to $893.1M in fiscal 2025. Capital expenditures were highest in fiscal 2023, at $119.1M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $990.8M | $97.7M | $893.1M |
| 2024ended Dec 31, 2024 | $609.4M | $109.5M | $499.9M |
| 2023ended Dec 31, 2023 | $715.3M | $119.1M | $596.2M |
| 2022ended Dec 31, 2022 | $436.2M | $83.8M | $352.4M |
| 2021ended Jan 1, 2022 | $357.7M | $54.5M | $303.2M |
| 2020ended Jan 2, 2021 | $435.4M | $47.5M | $387.9M |
| 2019ended Dec 28, 2019 | $408.5M | $92.4M | $316.1M |
| 2018ended Dec 29, 2018 | $362.7M | $77.6M | $285.1M |
| 2017ended Dec 30, 2017 | $291.9M | $65.2M | $226.7M |
| 2016ended Dec 31, 2016 | $442.3M | $65.2M | $377.1M |
Fiscal years as REGAL REXNORD CORP reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on REGAL REXNORD CORP
- The revenue of REGAL REXNORD CORP
- The profitability of REGAL REXNORD CORP
- The debt of REGAL REXNORD CORP
- The dividends of REGAL REXNORD CORP
- All of REGAL REXNORD CORP's financials, charted
Companies of a similar size
- MUSAMURPHY USA INC.
- PTGXProtagonist Therapeutics, Inc
- BXPBXP, INC.
- NTSKNetskope, Inc.
- BIOBIO-RAD LABORATORIES, INC.
Not investment advice. This page shows what REGAL REXNORD CORP filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.